Optimizing first-line TKI treatment efficacy in PD-L1-positive EGFR-mutated NSCLC: the impact of antiangiogenic agents
Xuanhong Jin(Sir Run Run Shaw Hospital), Liangkun You(Zhejiang University), Cheng Cheng(Jilin University), Xinyu Zhu(Huazhong Agricultural University), Hangchen Shen(Sir Run Run Shaw Hospital), Hongming Pan(Sir Run Run Shaw Hospital), Kailai Yin(Wenzhou Medical University), Pan Yang(Army Medical University)
Cited by 3
Related Papers
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for HER2-negative advanced gastric cancer (KEYNOTE-859): a multicentre, randomised, double-blind, phase 3 trial
|The Lancet Oncology|2023|663
Donafenib Versus Sorafenib in First-Line Treatment of Unresectable or Metastatic Hepatocellular Carcinoma: A Randomized, Open-Label, Parallel-Controlled Phase II-III Trial
|Journal of Clinical Oncology|2021|417
Effect of Fruquintinib vs Placebo on Overall Survival in Patients With Previously Treated Metastatic Colorectal Cancer
|JAMA|2018|410
Sintilimab Plus Chemotherapy for Unresectable Gastric or Gastroesophageal Junction Cancer
|JAMA|2023|384
<i>TP53</i> Germline Variations Influence the Predisposition and Prognosis of B-Cell Acute Lymphoblastic Leukemia in Children
|Journal of Clinical Oncology|2018|179